Raising awareness about adult autism spectrum disorder by Teodoro, Tomás & Salgado, José










Cartas ao Editor, Acta Med Port 2021 Nov;34(11):796-804
Raising Awareness about Adult Autism Spectrum 
Disorder
Sensibilizando para a Perturbação do Espetro do 
Autismo no Adulto
Keywords: Attention Deficit Hyperactivity Disorder; Autistic 
Disorder; Neurodevelopmental Disorders; Transition to Adult Care
Palavras-chave: Perturbação do Deficit de Atenção com Hiper- 
atividade; Perturbação Autística; Perturbação do Neurodesenvolvi-
mento; Transição para Assistência do Adulto
 Dear Editor,
 Martins Halpern et al1 presented the experience of their 
specialized center while highlighting the challenges of di-
agnosing and treating autism spectrum disorders in early 
infancy. However, problems in the approach of these and 
other neurodevelopmental disorders are not limited to the 
early stages of life. Their work prompted us to briefly high-
light challenges arising in other phases of the life cycle and 
raise awareness of this condition.
 Patients with neurodevelopmental disorders, including 
autism spectrum disorder (ASD) and attention deficit and 
hyperactivity disorder, are often lost in the transition from 
children and young people’s healthcare services to adult 
services.2,3 Patients who are not lost in this transition may 
prove even more challenging, since most have no previ-
ously known psychiatric history or a previously established 
diagnosis.3 Some individuals who suffer from these dis-
orders present milder symptoms and often remain undi-
agnosed until adulthood. When eventually presenting to 
adult psychiatry services, these diagnoses are often also 
overlooked, with patients frequently diagnosed with differ-
ent personality disorders (including schizoid and borderline 
personality disorder) or with other psychiatric comorbidi-
ties (depression, stress-related and anxiety disorders), and 
therefore deprived of specific psychosocial interventions or 
evidence-based treatments directed at the particular needs 
of patients with autism related disorders.2,4 Interestingly, in-
dividuals with high functioning ASD present more often to 
psychiatric services and yet they remain without a proper 
diagnosis until later stages in life.3
 Overall, available national clinical recommendations 
provide general advice suggesting the assessment of adults 
presenting with inadequate social interaction, cognitive and 
behavioural rigidity, restricted interests and previous medi-
cal history of neurodevelopmental disorders.1,5 Although it is 
useful, the translation of these general principles in every-
day clinical practice is not as straightforward as it may seem. 
Challenges include the clinical heterogeneity of ASD, rang-
ing from complex genetic conditions with learning disability 
to high functioning individuals who adapted and developed 
strategies to overcome autistic deficits.3,4 Conceptualization 
of neurodevelopmental disorders, their neurobiology and 
different ways in which they affect functioning, quality of life 
and overall medical care, need to be considered and prop-
erly studied in order to ensure that minimal standards in the 
provision of care to individuals are met, including a smooth-
er and well planned transition from child to adult healthcare 
services. Specific issues to be considered include the di-
agnostic challenges, psychiatric comorbidities, and lack of 
social support (reduced number of institutions, aging family 
caregivers, etc.). 
 The authors work in an institution with services provid-
ing care to adolescents and young adults in transition to 
adult psychiatric care (both in inpatient units and outpatient 
clinics), as well as a specialized outpatient clinic for patients 
with adult attention deficit disorder and neurodevelopmen-
tal disorders. This experience highlights the shortcomings 
felt in the care previously provided to these patients. The 
important message is that, although much has advanced 
since the initial descriptions of these disorders, there is still 
much to be done. It is essential to raise awareness and ad-
vocate for the specific medical and societal needs of adult 
individuals who suffer from the effect of these symptoms in 
their daily life, with profound impact in their general health 
and overall well-being.
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The EU Digital COVID Certificate: Should We 
Differentiate Between Previously Infected and Fully 
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Certificado Digital COVID da EU: Devemos Distinguir 
as Pessoas Previamente Infetadas das que Têm 
Vacinação Completa?
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 The EU Digital COVID Certificate will be a proof that a 
person has been vaccinated against COVID-19, received a 
negative test result, or recovered from COVID-19. The EU 
has set the maximum validity period of the certificate of re-
covery at 180 days. There is no maximum validity foreseen 
for vaccination certificates.1 
 What is the evidence behind this decision? 
 Previously infected individuals have very low risk for re-
infection at least six to eight months after the primary infec-
tion, as observed both in healthcare workers (HCW) and 
in the general population. And those who get infected are 
mainly asymptomatic or have non-severe symptoms.2-5
 A study performed in England with a population of HCW 
has found that those with previously positive SARS-CoV-2 
antibodies had a 99.8% lower risk of new infection com-
pared to participants with previously negative serology, 
when restricting reinfections to confirmed and probable 
cases.4
 The protection period conferred from previous infection 
is being extended as new evidence is available with the pro-
gression of the pandemic. A study with HCW in Ohio sug-
gests that SARS-CoV-2 infection may provide protection 
against reinfection for 10 months or longer.5 More recently, 
Turner et al have demonstrated that SARS-CoV-2 infection 
induces long-lived bone marrow plasma cells and memory 
B cells in humans.6 
 The progressive decay in antibody titers that has been 
documented is observed in other infections after vaccina-
tion and does not necessarily mean a waning of protec-
tion to reinfection. T-cell mediated immunity (T-CD4+ and 
T-CD8+ specific) seems more important than neutralizing 
antibodies for the clinical impact of the infection.7 
 The protection conferred was observed regardless of 
the clinical severity of the primary infection.4,5 In fact, the 
immunological priming is the same. Both symptomatic and 
asymptomatic previously infected people showed a similar, 
immediate and robust antibody production after a subse-
quent administration of one vaccine dose.8
 We already have good immunologic and clinical evi-
dence of long-lasting protection against reinfection in pa-
tients who recovered from infection. 
 What do we know about vaccinated people?
 The best results published regarding vaccine effective-
ness were those of Israel, with a follow-up period of seven 
days to three months after the second dose of the mRNA 
BNT162b2 vaccine. The protection was 92% against infec-
tion and 94% against symptomatic infection.9 
 Regarding efficacy against variants of concern (VOCs), 
no better protection is expected to be achieved by people 
who had been immunized through vaccination than by 
those who recovered from infection, since the immunologi-
cal response is directed towards multiple viral antigens and 
not just the spike protein.4,5 In fact, a recent retrospective 
cohort study from Israel showed that the immunity acquired 
through infection conferred a better and longer lasting pro-
tection against infection, symptomatic disease and hospital-
ization caused by the Delta variant of SARS-CoV-2, com-
pared to the BNT162b2 two-dose vaccine-induced immu-
nity.10
 The answer to the question whether the EU Digital 
COVID Certificate should differentiate between previously 
infected and fully vaccinated people should rely on the fact 
that, until now, previous infection has proved to be better 
and longer lasting than the vaccines.
 So why decide in the opposite way?
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